MC38 is a syngeneic colorectal cancer model which has been extensively used in the context of immune checkpoint inhibitor therapy as it has shown robust responses to anti PD1 and anti PDL1 antibodies. This evidence concerns the gene PDCD1 and colorectal cancer.